Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
-$0.22 today
- Market cap
- $255.25M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
Volume 0.26M
Average 0.74M
QTTB Operating Cash Flow
Cash generated by the company's core business operations during the period.
Q32 Bio Inc.NASDAQ: QTTB
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $6.34M (cash outflow) fell 49.2% year over year, ahead of the -58.3% change in trailing-twelve-month operating cash flow. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +45.2% a year.
Context
- Operating cash flow amounted to 62.4% of revenue in FY2025.
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -49.2% holds above the trailing-twelve-month pace of -58.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (33.54M) USD
- Year-over-year change
- +50.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.54M) | +50.5% |
| FY2024 | 2024-12-31 | (67.72M) | -262.6% |
| FY2023 | 2023-12-31 | (18.68M) | -70.5% |
| FY2022 | 2022-12-31 | (10.96M) | +90.0% |
| FY2021 | 2021-12-31 | (109.75M) | — |
Operating Cash Flow vs competitors
How QTTB compares with its peers on the latest reported figures
- QTTB's LTM Mar 2026 operating cash flow of $27.4M is the 4th largest of the 5 companies compared; the peer median is $39.19M.
- Its year-over-year change of -58.3% is the 4th highest of 5, against a peer median of -23.5%.
- Operating cash flow amounts to 51.0% of revenue for QTTB, versus a peer median of 38.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $68.21M | +123.6% | +24.0% | — | |
| LTM Mar 2026 | $47.1M | -21.0% | +5.6% | — | |
| LTM Mar 2026 | $31.28M | -26.0% | -3.8% | — | |
| LTM Mar 2026 | $27.4M | -58.3% | +45.2% | 51.0% | |
| LTM Mar 2026 | $14.11M | -73.7% | -1.9% | 38.0% | |
| Peer median (excluding QTTB) | $39.19M | -23.5% | +1.9% | 38.0% | |
Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (95.76M) | (42.81M) | (53.74M) | (47.73M) | 29.82M |
| Depreciation & Amortization | 9.54M | 370K | 499K | 487K | 391K |
| Deferred Income Tax | 0 | 2.43M | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 1.24M | 1.43M | 4.39M | 5.26M |
| Change in Working Capital | (41.8M) | 26.94M | 26.32M | (9.64M) | (4.04M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.49M) | (1.24M) | 2.03M | (1.04M) | (2.11M) |
| Other Working Capital | (39.32M) | 28.18M | 24.28M | (8.59M) | (1.93M) |
| Other Non-Cash Items | 18.27M | 876K | 6.82M | (15.22M) | (64.97M) |
| Operating Cash Flow | (109.75M) | (10.96M) | (18.68M) | (67.72M) | (33.54M) |
| Capital Expenditures | (2.4M) | (2.49M) | (5K) | (75K) | 0 |
| Acquisitions (Net) | 0 | 130M | 0 | 0 | 0 |
| Purchases of Investments | (97.39M) | (157.46M) | 0 | 0 | 0 |
| Sales of Investments | 49M | 65.46M | 0 | 20M | 0 |
| Other Investing Activities | 0 | (37.98M) | 0 | 0 | 7M |
| Investing Cash Flow | (50.79M) | (2.47M) | (5K) | 19.93M | 7M |
| Debt Repayment | 0 | 30M | 300K | 7M | (3.13M) |
| Common Stock Issued | 52.17M | 69K | 106K | 42M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 46.14M | 0 |
| Financing Cash Flow | 52.17M | 30.07M | 406K | 95.14M | (3.13M) |
| Effect of Forex Changes | (679K) | 0 | 9.91M | 0 | 0 |
| Net Change in Cash | (109.05M) | 16.65M | (8.37M) | 47.35M | (29.67M) |
| Free Cash Flow | (112.15M) | (13.44M) | (18.68M) | (67.79M) | (33.54M) |
Q32 Bio Inc.
NASDAQ:QTTB
Intrinsic Alpha fair value
Locked
Current Price
$8.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.